Fusion Inhibitors Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

Fusion inhibitors are a class of antiviral drugs designed to combat viral infections by targeting the fusion process of viral particles with host cells. These inhibitors interact with specific receptors or molecules involved in the fusion step of viral entry. By doing so, they prevent the virus from fusing with the host cell membrane and entering the cell, thereby halting the infection at its initial stage. One of the most well-known applications of fusion inhibitors is in treating HIV/AIDS. HIV fusion inhibitors, like enfuvirtide, block the fusion of the virus with the host CD4+ T cells, reducing viral replication and slowing disease progression. Additionally, fusion inhibitors are under investigation for other viral infections, such as respiratory syncytial virus (RSV) and herpesvirus, showing the potential to inhibit viral entry and replication. According to the World Health Organization (WHO), HIV/AIDS remains a major global health issue, with approximately 38 million people living with HIV worldwide. In this context, fusion inhibitors offer a critical line of defense in antiretroviral therapy, providing hope for improved outcomes and quality of life for HIV-positive individuals. As research advances, fusion inhibitors may continue to be a valuable tool in the fight against various viral diseases, offering innovative treatment options and contributing to global efforts to combat infectious diseases. Extensive research is being conducted globally to discover new and novel molecules to be used, like palivizumab, that is used for the treatment of many indications like Respiratory tract diseases. The development and launch of new products will thus increase the market's revenue in the forecasted years.

Several of these inhibitors are on the market, while many are in ongoing clinical trials. Various companies have various products in their pipelines, with 14 products in various stages of clinical trials – 1 in Phase 4, 2 in Phase 3, 5 in Phase 2, and 1 in Phase 1 of the clinical trials.

Key Development of Fusion Inhibitors

• In December 2022, National Medical Products Administration (NMPA) accepted Ark Biopharmaceuticals’s Ziresovir (AK0529) for priority review of NDA for the treatment of RSV infection.

Approved Fusion Inhibitors molecules

• Synagis (palivizumab)

Drugs in the Pipeline of Fusion Inhibitors

• EDP-938
• ziresovir (AK0529)
• gontivimab (ALX-0171)
• presatovir (GS-5806)
• clesrovimab (MK-1654)
• MDT-637
• MB05 (palivizumab biosimilar)
• TNM001

Clinical Activity and Developments of Fusion Inhibitors

As of July 2023, various companies have approximately 14 products for 119 diseases. For these diseases, many trials are being conducted by players globally. For instance,

• Merck (MSD) is conducting a Phase 3 clinical trial to evaluate the safety, efficacy, and pharmacokinetics of Clesrovimab (MK-1654) in infants and children at increased risk for severe RSV disease that is expected to complete by April 2028.
• Enanta Pharmaceuticals is conducting a Phase 2 clinical trial to evaluate the effects of EDP-938 in Hematopoietic Cell Transplant recipients with Acute Respiratory Syncytial Virus infection of the Upper Respiratory Tract that is estimated to complete by April 2024.
• Enanta Pharmaceuticals is conducting a Phase 2 clinical trial to Evaluate the efficacy and safety of EDP-938 in non-hospitalized adults with Acute Respiratory Syncytial Virus infection who are at high risk for complications that is expected to complete by April 2024.